Richard Shea
Director/Board Member at SYNLOGIC, INC.
Net worth: 930 $ as of 30/04/2024
Richard Shea active positions
Companies | Position | Start | End |
---|---|---|---|
SYNLOGIC, INC. | Director/Board Member | 28/08/2017 | - |
Independent Dir/Board Member | 28/08/2017 | - | |
Synlogic Operating Co., Inc.
Synlogic Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Synlogic Operating Co., Inc. operates as a biopharmaceutical company. The firm's pipeline focuses on rare diseases, the company is leveraging the broad potential of its synthetic biotics platform for novel drug development in major disease areas through partnerships with pharmaceutical and biotechnology companies. It also engages in development of synthetic biotics-based treatment for inflammatory bowel disease. The company was founded by James J. Collins and Timothy K. Lu in 2014 and is headquartered in Cambridge, MA. | Director/Board Member | - | - |
Career history of Richard Shea
Former positions of Richard Shea
Companies | Position | Start | End |
---|---|---|---|
SYNDAX PHARMACEUTICALS, INC. | Comptroller/Controller/Auditor | - | 13/07/2020 |
Director/Board Member | 23/01/2014 | 13/02/2017 | |
Director of Finance/CFO | 13/02/2017 | 13/07/2020 | |
Independent Dir/Board Member | 23/01/2014 | 13/02/2017 | |
Treasurer | 13/02/2017 | 13/07/2020 | |
MOMENTA PHARMACEUTICALS, INC. | Director/Board Member | 01/07/2007 | 10/03/2015 |
Director of Finance/CFO | 01/10/2003 | 01/12/2016 | |
Variagenics, Inc.
Variagenics, Inc. Miscellaneous Commercial ServicesCommercial Services Variagenics, Inc. develops molecular diagnostic tests by identifying genetic markers associated with response to cancer therapies, with the goal of optimizing patient care through both biopharmaceutical collaborations and its own internal research programs | Chief Operating Officer | 01/02/1999 | 01/04/2003 |
Director of Finance/CFO | 01/02/1999 | 01/04/2003 | |
Genetics Institute LLC
Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA. | Director of Finance/CFO | 01/01/1992 | 01/01/1999 |
Training of Richard Shea
Boston University | Masters Business Admin |
Princeton University | Undergraduate Degree |
Statistics
International
United States | 9 |
Operational
Director/Board Member | 4 |
Director of Finance/CFO | 4 |
Independent Dir/Board Member | 2 |
Sectoral
Health Technology | 6 |
Consumer Services | 3 |
Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
SYNDAX PHARMACEUTICALS, INC. | Health Technology |
SYNLOGIC, INC. | Health Technology |
Private companies | 4 |
---|---|
Momenta Pharmaceuticals, Inc.
Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
Variagenics, Inc.
Variagenics, Inc. Miscellaneous Commercial ServicesCommercial Services Variagenics, Inc. develops molecular diagnostic tests by identifying genetic markers associated with response to cancer therapies, with the goal of optimizing patient care through both biopharmaceutical collaborations and its own internal research programs | Commercial Services |
Genetics Institute LLC
Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA. | Health Technology |
Synlogic Operating Co., Inc.
Synlogic Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Synlogic Operating Co., Inc. operates as a biopharmaceutical company. The firm's pipeline focuses on rare diseases, the company is leveraging the broad potential of its synthetic biotics platform for novel drug development in major disease areas through partnerships with pharmaceutical and biotechnology companies. It also engages in development of synthetic biotics-based treatment for inflammatory bowel disease. The company was founded by James J. Collins and Timothy K. Lu in 2014 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Richard Shea
- Experience